NCT07776288Not yet recruitingPhase 2
Combined Antioxidant Therapy for Acute Myocardial Infarction
Pharmacological Protection Against Reperfusion Injury in Patients With Acute Myocardial Infarction: a Phase 2 Randomized Controlled Trial of a Combined Antioxidant Therapy (CAT-AMI Trial)
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if a combined antioxidant therapy (CAT) can reduce heart damage caused by the return of blood flow after blocked arteries are reopened in adults with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). It will also learn about the safety of this treatment. The main questions it aims to answer are: 1. Does combined antioxidant therapy lower infarct size, measured by cardiac magnetic resonance imaging (CMR), compared with placebo? 2. Does combined antioxidant therapy improve heart function, blood biomarkers of heart injury, and short-term clinical outcomes? 3. What problems do participants have when receiving the therapy? Researchers will compare CAT to placebo (a look-alike infusion with no active drug) to see if the treatment lowers infarct size after STEMI. Participants will: * Be randomly assigned to receive either CAT or placebo * Receive the study infusion before and during primary PCI, in addition to standard treatment for STEMI * Have blood tests to measure heart injury, oxidative stress, inflammation, and drug levels * Undergo cardiac magnetic resonance imaging about 3 to 7 days after STEMI. * Be followed for clinical outcomes and safety for 30 days.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- University of Chile
- Diseases
- Coronary artery disease
- NCT number
- NCT07776288
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 46
- From 1 Sept 2026 to the primary completion date, 31 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior myocardial infarction
- Prior thrombolytic therapy for the index event.
- Prior coronary artery bypass graft (CABG) surgery
Other illness
- Advanced heart failure, defined as New York Heart Association (NYHA) class III or IV
- Implanted cardiac device, including pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization device
- Other contraindications to cardiac magnetic resonance imaging (CMR), according to local protocol
Lab values
- Chronic kidney disease, defined as serum creatinine greater than 1.5 mg/dL or dialysis.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Other
- Cardiogenic shock, defined as Society for Cardiovascular Angiography and Interventions (SCAI) shock class D or E.
- Liver cirrhosis
- Nephrolithiasis
- Life expectancy less than 6 months
- Pregnancy
- Claustrophobia
Who the study is looking for
- Age 18 years or older
- First anterior ST-segment elevation myocardial infarction (STEMI)
- Symptom onset within 6 hours before presentation
- Eligible for primary percutaneous coronary intervention (PCI)
- Provision of informed consent by the participant or a legally authorized representative, according to local ethics requirements
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital San Juan de Dios Coordinator of this site? Confirm its status | Santiago | Chile | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.